Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Rüdiger Liersch"'
Autor:
Enriqueta Felip, Hiroshi Tanaka, Silvia Novello, Hao Xu, Heather Wakelee, Barbara Gitlitz, Martin Reck, Wei Zou, Elizabeth Bennett, Mark McCleland, Caicun Zhou, Satoshi Oizumi, Anna Kryzhanivska, Virginia McNally, Marcus Ballinger, Meghna Das Thakur, Steven L McCune, John Hamm, Minu K Srivastava, Nasser Altorki, Rüdiger Liersch
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Tumor samples from the phase III IMpower010 study were used to compare two programmed death-ligand 1 (PD-L1) immunohistochemistry assays (VENTANA SP263 and Dako 22C3) for identification of PD-L1 patient subgroups (negative, positive, low,
Externí odkaz:
https://doaj.org/article/cfe63add9cfe46b48a019fc54672b05f
Autor:
Florian Simon, Rudy Ligtvoet, Thomas Noesslinger, Jan-Paul Bohn, Julia Von Tresckow, Rüdiger Liersch, Tobias Gaska, Kathleen Jentsch-Ullrich, Michael Koenigsmann, Thomas Wolff, Ingo Schwaner, Dominik Wolf, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Karl-Anton Kreuzer, Sandra Robrecht, Anna-Maria Fink, Moritz Fürstenau, Kirsten Fischer, Valentin Goede, Michael Hallek, Barbara Eichhorst
Publikováno v:
HemaSphere, Vol 7, p e3844763 (2023)
Externí odkaz:
https://doaj.org/article/8a43f0f54e4c40a8b2e60240c8a0ce55
Autor:
Nadine Kutsch, Christian Pallasch, Eugen Tausch, Volkmar Böhme, Matthias Ritgen, Rüdiger Liersch, Alexander Wacker, Georg Jacobs, Ralf Ulrich Trappe, Peter Dreger, Kirsten Fischer, Anna-Maria Fink, Stephan Stilgenbauer, Shuyan Zhai, Biao Li, Juliane M. Jürgensmeier, Nishanthan Rajakumaraswamy, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst
Publikováno v:
HemaSphere, Vol 6, Iss 4, p e692 (2022)
Externí odkaz:
https://doaj.org/article/cc1dd22b903a4e9bb9d8ee19e48800b6
Autor:
Martin Sebastian, Andreas Gröschel, Sylvia Gütz, Holger Schulz, Harald Müller-Huesmann, Rüdiger Liersch, Eyck von der Heyde, Jörg Wiegand, Dieter Ukena, Joachim Bargon, Wolfgang Schütte, Jorge Riera-Knorrenschild, Jürgen R. Fischer, Frank Griesinger, Victoria Allan, Daniela Waldenberger, Christian Schumann
Publikováno v:
Journal of Immunotherapy. 45:89-99
Nivolumab was the first immune checkpoint inhibitor approved for use in advanced non-small cell lung cancer (NSCLC). This noninterventional, prospective cohort study investigates real-world effectiveness of nivolumab in pretreated NSCLC patients in G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c96f124ee4d0ff14ff0f8d636144e126
https://doi.org/10.1097/cji.0000000000000397
https://doi.org/10.1097/cji.0000000000000397
Autor:
Raoul Herbrecht, Robert Pack, Monika Wroclawska, Rüdiger Liersch, Burkhard Schmidt, Fiorenza Barraco, Heinz Gisslinger, Reinier Raymakers, Andreas Reiter, Richard Greil, Divyadeep Karumanchi, Wolfgang Willenbacher, Karin Burock
Publikováno v:
British Journal of Haematology. 191:764-774
Primary objective of this non-interventional, post-authorisation safety study was to provide real-world safety data [incidence of adverse drug reactions (ADRs)/serious adverse events (SAEs)] on adult patients with myelofibrosis exposed/or not exposed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4551258c6d7675271bfc75ccafbed541
https://doi.org/10.1111/bjh.16729
https://doi.org/10.1111/bjh.16729
Autor:
Nadine Kutsch, Christian Pallasch, Eugen Tausch, Volkmar Böhme, Matthias Ritgen, Rüdiger Liersch, Alexander Wacker, Georg Jacobs, Ralf Ulrich Trappe, Peter Dreger, Kirsten Fischer, Anna-Maria Fink, Stephan Stilgenbauer, Shuyan Zhai, Biao Li, Juliane M. Jürgensmeier, Nishanthan Rajakumaraswamy, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst
Publikováno v:
HemaSphere. 6(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7463ecb375d14d2e1c9f8116b75635a5
https://pubmed.ncbi.nlm.nih.gov/35284802
https://pubmed.ncbi.nlm.nih.gov/35284802
Autor:
Andreas Neubauer, Ralf Jany, Christian Rübe, Rainer Fietkau, Severin Daum, Georg Stüben, Wolfgang E. Berdel, Martin Wilhelm, Markus Tiemann, Georg Lenz, Normann Willich, Wolfgang Fischbach, Carsten Hirt, Rüdiger Liersch, Kay Willborn, Peter Möller, Martin Bentz, Clemens F. Hess, Andreas Probst, Gabriele Reinartz, Jürgen Schultze, Regina P. Pyra, Oliver Micke, Christiane Pott, Hans Theodor Eich
Publikováno v:
Strahlentherapie und Onkologie. 195:544-557
Long-term impact of stage-adapted field reduction in a large cohort of gastric marginal zone lymphoma (gMZL) patients treated conservatively with curative radiation therapy (RT).Prospective analysis of paper records of 290 patients with stage IE-IIE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e94b449829d73d7b71f4726511cf42b2
https://doi.org/10.1007/s00066-019-01446-5
https://doi.org/10.1007/s00066-019-01446-5
Autor:
Rüdiger Liersch, Mine Arslan-Kirchner, Jörg Schmidtke, Diana Elligsen, Brigitte Pabst, Krishna K. Singh, Stefanie Schubert
Publikováno v:
Journal of Molecular and Cellular Cardiology. 42:352-356
Marfan syndrome is caused by mutations in fibrillin-1, a large gene spanning approximately 200 kb of genomic DNA on chromosome 15q21. So far, more than 600 different mutations have been identified, accounting for 60-90% of all Marfan syndrome cases,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03469e363493330ad41a943677c19a27
https://doi.org/10.1016/j.yjmcc.2006.11.006
https://doi.org/10.1016/j.yjmcc.2006.11.006
Autor:
Torsten, Kessler, Michael, Bayer, Christian, Schwöppe, Rüdiger, Liersch, Rolf M, Mesters, Wolfgang E, Berdel
Publikováno v:
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 180
Targeted therapies against cancer have become more and more important. In particular, the inhibition of tumor angiogenesis and vascular targeting have been the focus of new treatment strategies. Numerous new substances were developed as angiogenesis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8e78b246bd9ac8de0f8c674613cf30c3
https://pubmed.ncbi.nlm.nih.gov/20033382
https://pubmed.ncbi.nlm.nih.gov/20033382
Autor:
Michael Bayer, Wolfgang E. Berdel, Torsten Kessler, Christian Schwöppe, Rüdiger Liersch, Rolf M. Mesters
Publikováno v:
Angiogenesis Inhibition ISBN: 9783540782803
Targeted therapies against cancer have become more and more important. In particular, the inhibition of tumor angiogenesis and vascular targeting have been the focus of new treatment strategies. Numerous new substances were developed as angiogenesis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd9d0c097b1b437c33324f2c4efbdf0b
https://doi.org/10.1007/978-3-540-78281-0_9
https://doi.org/10.1007/978-3-540-78281-0_9
